Finance

Lists
Q3 2026 earnings • released • Revenue miss -2.00%
See results
4151:TYO
Kyowa Kirin Co Ltd
Â¥2,445.00
-6.70%
(-175.50) 1D
Nov 6, 1:02:54 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4151...
Open
Â¥2,544
High
Â¥2,564
Low
Â¥2,442
Mkt. cap
1.29T
Avg. vol.
1.97M
Volume
941.90K
Dividend
2.74%
Quarterly dividend
Â¥17
Ex-dividend date
Jun 29, 2026
P/E ratio
14.86
52-wk high
Â¥2,912
52-wk low
Â¥2,109
EPS
Â¥164
Shares outstanding
547.44M
No. of employees
5K
Open
Â¥2,544
High
Â¥2,564
Low
Â¥2,442
Mkt. cap
1.29T
Avg. vol.
1.97M
Volume
941.90K
Dividend
2.74%
Quarterly dividend
Â¥17
Ex-dividend date
Jun 29, 2026
P/E ratio
14.86
52-wk high
Â¥2,912
52-wk low
Â¥2,109
EPS
Â¥164
Shares outstanding
547.44M
No. of employees
5K
News stories
From web sources and news partners
Profile
Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Wikipedia
About Kyowa Kirin Co Ltd
CEOMasashi Miyamoto
Employees5.16K
FoundedJul 1, 1949
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 2, 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (JPY)
121.32B / 123.80B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
147.38B
118.47B
145.16B
121.32B
Cost of goods sold
37.87B
30.22B
36.13B
-
Cost of revenue
37.87B
30.22B
36.13B
-
Research and development expenses
24.35B
27.16B
19.16B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31.35B
41.07B
43.74B
-
Operating expense
72.15B
71.01B
94.49B
-
Total operating expenses
110.02B
101.23B
130.62B
-
Operating income
37.35B
17.23B
14.55B
-
Other non operating income
13.50B
-7.71B
7.71B
-
EBT including unusual items
39.30B
13.93B
23.54B
-
EBT excluding unusual items
51.23B
13.93B
23.54B
-
Income tax expense
4.86B
1.89B
4.96B
-
Effective tax rate
12.36%
13.59%
21.05%
-
Other operating expenses
3.92B
-
28.59B
-
Net income
34.44B
12.03B
18.58B
-
Net profit margin
23.37%
10.16%
12.80%
-
Earnings per share
-
-
-
-
Interest and investment income
2.71B
5.68B
1.58B
-
Interest expense
-28.00M
-2.27B
-
-
Net interest expenses
2.68B
3.41B
1.58B
-
Depreciation and amortization charges
12.54B
-
-2.78B
-
EBITDA
44.74B
24.88B
22.32B
-
Gain or loss from assets sale
2.77B
-
5.56B
-
Upcoming events
AI content may include mistakes. Learn more
Google apps